# A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Source: https://onco.cc/trials/nct06783647/  
OnCo record `nct06783647` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Docetaxel, Bevacizumab, Pemetrexed and Carboplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] is a phase 2 interventional study registered as NCT06783647 by Nanjing Leads Biolabs Co.,Ltd, with 250 participants planned, started 2025-06-11 and due to reach its primary completion in 2026-12-24. Interventions recorded: LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection, Pemetrexed Disodium for Injection, Paclitaxel Injection and Carboplatin Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06783647
- Phase: 2
- Setting: An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 01(NSCLC)]
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06783647: https://clinicaltrials.gov/study/NCT06783647

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct06783647.json